Equity Field Notes from temporal sources

[DanWebzster]

PRTK has PDUFA for its IV-Oral Antibiotic 10/2/18.

Indications are CABP & Skin Infection.

The hook for this treatment is that hospital patients can be started on IV and moved to oral when they are dismissed. This versatility will be a competitive economic advantage allowing patients to be dismissed in as little as 3 days.

PRTK's compound is broader sprectrum , covering some Gram negs that now require two antibiotics in hospital (that do not have an oral option) and therefore a longer time in hosptial (5-7 days)

The cheapest competing molecule is the generic zyvox (linezolid) Unfortunately, it is associated with Serotonin Syndrome in patients taking SSRIs.